US Stem Cell Inc (USRM)

[Dragon Lady]

10-Q MASSIVE dilution:

Page 1:
"As of August 1, 2014, there were 517,272,472 outstanding shares of the Registrant’s common stock, par value $0.001 per share."

That's 466 MILLION or so, to 517 MILLION in a single quarter, WOW !! That's 51 MILLION shares of dilution in one qtr, the pace of dilution appears to be accelerating. Pretty clear IMO, why the increase in authorized to 2 BILLION shares was needed. That 517 million shares is not even the "fully diluted" shares, which will be an even bigger number.

Page 9: FULLY DILUTED SHARES HUGE
"Fully diluted shares outstanding were 588,670,163 and 290,900,920 for the three months ended June 30, 2014 and 2013, respectively and 553,719,873 and 264,534,723 for the six months ended June 30, 2014 and 2013, respectively."

So they pretty much doubled the shares outstanding (fully diluted) in a single yr over yr period from 290 mil to almost 600 mil now.

Clear as a bell IMO, why the 2 BILLION authorization was needed- there gonna hit that 970 MILLION mark pretty quick, now that fully diluted is bumping 600 MILLION already. Holy smokes.

Almost no cash left as is typical.
Page 4:
Cash and cash equivalents: $91,221.00

So they finished the qtr nearly cash broke again. $91K bucks left.

Net loss from operation for the qtr, just a little bit lower than usual:
Page 5:
Net Loss From Operations: (458,048)

So, again, any "revenue" barely made a dent or a difference IMO. Barely lowered the net loss from yr over yr, or qtr over qtr- just eaten up in their high expenses, typical IMO.

And, once again, almost nothing went to R&D out off all those expenses and costs:
Page 5:
Research and Development: $15,478

A grand total of about $5K a month to R&D for a "medical R&D company" who's supposedly running or gonna run phase II/III trials? That's about $5K a month, the same amount they paid for "one month's service" to a penny stock promotion firm, as disclosed by smallcapvoice.

Looks pretty much like a near carbon copy of any of their last several 10-Q's IMO. Cash poor, high expenses, nearly nothing spent on R&D, blah, blah, blah. Will read it cover to cover later and see what else is buried in it.

The dilution is beyond what I even guessed, that number is mega huge IMO. And I believe explains the need to up the authorized, so they just picked a huge number like 2 BILLION IMO, to give um lots of room to just keep on a dilutin, since that seems to be the only "norm" for this one as I see it.